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Abstract
Memory loss is one of the hallmark symptoms of Alzheimer’s disease (AD). It has been proposed that soluble amyloid-beta
(Abeta) oligomers acutely impair neuronal function and thereby memory. We here report that natural Abeta oligomers
acutely impair contextual fear memory in mice. A natural Abeta oligomer solution containing Abeta monomers, dimers,
trimers, and tetramers was derived from the conditioned medium of 7PA2 cells, a cell line that expresses human amyloid
precursor protein containing the Val717Phe familial AD mutation. As a control we used 7PA2 conditioned medium from
which Abeta oligomers were removed through immunodepletion. Separate groups of mice were injected with Abeta and
control solutions through a cannula into the lateral brain ventricle, and subjected to fear conditioning using two tone-shock
pairings. One day after fear conditioning, mice were tested for contextual fear memory and tone fear memory in separate
retrieval trials. Three experiments were performed. For experiment 1, mice were injected three times: 1 hour before and
3 hours after fear conditioning, and 1 hour before context retrieval. For experiments 2 and 3, mice were injected a single
time at 1 hour and 2 hours before fear conditioning respectively. In all three experiments there was no effect on tone fear
memory. Injection of Abeta 1 hour before fear conditioning, but not 2 hours before fear conditioning, impaired the
formation of a contextual fear memory. In future studies, the acute effect of natural Abeta oligomers on contextual fear
memory can be used to identify potential mechanisms and treatments of AD associated memory loss.
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Introduction
Alzheimer’s disease (AD) is characterized by a severe loss of
memory function. It has been proposed that AD associated
memory loss is caused by soluble amyloid-beta (Abeta) oligomers,
especially during early stages of AD before significant neuronal
cell death has occurred [1,2]. This model is supported by a
number of observations. First, soluble Abeta levels, but not
plaque number or insoluble Abeta levels, correlate with the
severity of AD [3,4]. Second, in AD mouse models memory loss is
observed before the formation of plaques but during and
correlating with an increase in Abeta oligomers [5,6,7]. Third,
Abeta oligomers isolated from AD brains can impair memory
when injected in rodent brains [8]. Interestingly, the effects of
Abeta oligomers on memory are acute and reversible [7,8,9].
This suggests that, at least during the early stages of AD, memory
loss might be reversed by preventing the formation or action of
Abeta oligomers.
It is not clear how Abeta oligomers impair memory.
Extracellular Abeta oligomers are able to bind to neurons, and
a number of molecules have been proposed as binding sites for
Abeta oligomers [10,11,12]. There is an ongoing effort to
determine which of these binding sites are essential for the
cognitive effects of Abeta oligomers [13,14]. Despite uncertainty
about the critical binding site(s), there is growing consensus that
binding of Abeta oligomers to neurons in the hippocampus
impairs synaptic plasticity [8,10,15,16]. Impairment of hippo-
campal synaptic plasticity by Abeta oligomers is an attractive
candidate mechanism for AD associated memory loss, which is
characterized by an early and severe loss of hippocampus
dependent memories.
The aim of this study was to test if natural Abeta oligomers can
impair fear conditioning in mice. We use the term natural Abeta
oligomers to refer to Abeta oligomers that are produced by cells,
as opposed to synthetic Abeta oligomers that are produced in-
vitro. The source of Abeta is an important consideration [1,17].
For example, natural Abeta oligomers can impair memory and
long-term potentiation at doses a hundred to thousand times
lower than effective doses of synthetic Abeta oligomers [18,19].
Fear conditioning is impaired in AD patients [20,21], and in
transgenic AD mouse models [22]. In order to further test if
soluble Abeta oligomers play a causative role in AD associated
memory loss, it is important to verify that impaired fear
conditioning can be caused by natural Abeta oligomers. We
therefore tested the effects of natural Abeta oligomers on two
types of memory that result from fear conditioning, one
dependent on the hippocampus (contextual fear memory) and
one independent from the hippocampus (tone fear memory) [23].
We found that natural Abeta oligomers acutely impaired the
formation of a contextual fear memory.
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Natural Abeta oligomer solution and injection
Figure 1A shows that the natural Abeta oligomer solution used
in this study contained a mixture of Abeta monomers, dimers,
trimers, and tetramers. After three rounds of immunodepletion no
Abeta oligomers could be detected, confirming the absence of
Abeta oligomers in the control solution. The Abeta oligomer
solution also contained secreted amyloid-precursor protein (sAPP).
However, sAPP was still present after immunodepletion (figure
S1). Therefore, any differences between the effects of the Abeta
oligomer solution and the control solution had to be caused by
Abeta oligomers. The Abeta oligomer solution contained between
12,000–14,000 pg/ml of total Abeta42 as measured by ELISA.
This concentration is comparable to similar preparations used in
earlier studies, and comparable to Abeta detected in human
cerebrospinal fluid [15]. Figure 1B shows the location in the lateral
brain ventricle where Abeta and control solutions were injected.
Experiment 1: repeated Abeta injection
Figure 2 shows the design and results of experiment 1. Repeated
injection of Abeta oligomers had no effect on baseline freezing or
fear conditioning, as indicated by similar freezing levels for both
groups at the start and end of fear conditioning on day 1.
Repeated Abeta injection resulted in a significantly lower freezing
score on day 2 during the context retrieval trial (t(9)=3.25,
P=0.010), indicating an impairment in contextual fear memory.
There was no difference between the 2 groups during the tone
retrieval trial, with similar freezing scores before and after the
onset of the tone. The data show that natural Abeta oligomers
induced a specific impairment in contextual fear memory, and that
they did not affect tone fear memory.
Experiment 2: single Abeta injection 1 hour before fear
conditioning
Figure 3 shows the design and results of experiment 2. Injection
of Abeta 1 hour before fear conditioning had no effect on baseline
freezing or fear conditioning on day 1. On day 2, the Abeta
injected group had a significantly lower average freezing score
during the context retrieval trial compared with the control group
(t(16)=2.18, P=0.044). No effect was found on freezing during
the tone retrieval trial. Again, similar to experiment 1, natural
Abeta oligomers impaired contextual fear memory but not tone
fear memory.
Experiment 3: single Abeta injection 2 hours before fear
conditioning
Figure 4 shows the design and results of experiment 3. Injection
of Abeta 2 hours before fear conditioning had no effect on fear
conditioning on day 1. There was no effect on the retrieval of the
context fear memory and the retrieval of the tone fear memory on
day 2. The data show that natural Abeta oligomers injected
2 hours before fear conditioning did not impair contextual and
tone fear memories.
Effects of control injections
Figure S2 shows a comparison between the three control groups
from experiment 1–3 and a group of mice that was not subjected
to surgery and injection. Repeated control injections increased
freezing during the context retrieval trial (figure S2A; t(10)=3.79,
P=0.004). Therefore, for future experiments single injection
might be preferred, or alternatively, habituation to injection might
be required to prevent possible stress effects caused by repeated
injections. Importantly, the surgery and control solution had no
effect on either contextual fear memory or tone fear memory, as
indicated by similar freezing scores for mice injected once with a
single control injection and mice that were not subjected to surgery
and injection (figure S2B–C).
Discussion
The main conclusion from this study is that natural Abeta
oligomers can acutely impair the formation of a contextual fear
memory. This conclusion is supported by three experiments that
used different time points of Abeta injection. The first experiment
used repeated injection before and after fear conditioning and
before retrieval. This resulted in impaired retrieval of contextual
fear memory. In order to determine which time point caused this
effect, we performed a second experiment with a single injection 1
hour before fear conditioning. This again resulted in impaired
retrieval of contextual fear memory. In order to determine if this
was caused by an acute effect on fear conditioning or a delayed
effect on context fear retrieval, we performed a third experiment
with a single Abeta injection 2 hours before fear conditioning.
This had no effect on the retrieval of contextual fear memory,
indicating that the single Abeta injection did not have a lasting
effect causing impaired retrieval one day later. Therefore, we
Figure 1. Natural Abeta oligomer solution and injection. A) Blot
image showing the presence of Abeta monomers, dimers, trimers, and
tetramers in the Abeta solution. The 6E10 antibody was used for
detection of Abeta oligomers that were removed from the Abeta
solution using immunoprecipitation with A/G beads and 4G8 antibody
(IP1, IP2, IP3: oligomers bound to beads used for first, second, and third
immunoprecipitation). No oligomers were detected after three rounds
of immunoprecipitation, which confirmed the absence of Abeta
oligomers in the control solution (see ‘‘Materials and Methods’’ for a
detailed description of how Abeta and control solutions were
generated). B) Diagram showing the location of the guide cannula
(green) and the injector cannula (red) in a Nissl-stained coronal section
of the mouse brain [38]. The tip of the guide cannula stopped just
above the corpus callosum. The tip of the injection cannula extended
into the lateral ventricle.
doi:10.1371/journal.pone.0029940.g001
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resulted in an Abeta concentration around the time of fear
conditioning that acutely impaired the formation of a contextual
fear memory. The lack of effect of Abeta injected 2 hours before
fear conditioning might have been caused by the reported 2 hour
half-life of Abeta in the brain [24]. The impaired retrieval of the
Figure 2. Experiment 1: repeated Abeta injection. Top) Diagram showing the design of experiment 1. Separate groups of mice were injected
three times with either control or Abeta solution. Bottom) Graphs showing average freezing scores during fear conditioning on day 1 and the two
retrieval trials on day 2 (see ‘‘Materials and Methods: Analysis of freezing behavior’’ for explanation of intervals on the X axis). Mice injected with the
Abeta solution (n=5) had significantly lower freezing scores during the context fear retrieval trial as compared with mice injected with the control
solution (n=6). Error bars are standard errors of means. * P,0.05.
doi:10.1371/journal.pone.0029940.g002
Figure 3. Experiment 2: single Abeta injection 1 hour before fear conditioning. Top) Diagram showing the design of experiment 2.
Separate groups of mice were injected one time with either control or Abeta solution 1 hour before fear conditioning. Bottom) Graphs showing
average freezing scores during fear conditioning on day 1 and the two retrieval trials on day 2. Mice injected with the Abeta solution (n=8) had
significantly lower freezing scores during the context fear retrieval trial as compared with mice injected with the control solution (n=10). Error bars
are standard errors of means. * P,0.05.
doi:10.1371/journal.pone.0029940.g003
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caused by a state-dependent effect, meaning the internal state of
the mice during retrieval differed from their internal state during
fear conditioning. In experiment 1 the mice were injected both
before fear conditioning and before retrieval and therefore
presumably were in the same state, which nevertheless still
resulted in an impaired contextual fear memory. In summary, the
data indicate that natural Abeta oligomers have an acute effect
during or shortly after fear conditioning, which results in the
impaired formation of a contextual fear memory.
An acute effect of Abeta oligomers during or shortly after fear
conditioning would impact learning or consolidation respectively.
Effects on learning have to be interpreted with caution, since they
might be caused by impaired detection of the conditioned stimulus
(CS: context) or the unconditioned stimulus (US: footshock). In
none of the three experiments we observed an effect of Abeta on
the formation and retrieval of a tone fear memory. This shows that
Abeta injection did not impair hearing function or shock sensation.
In addition, Abeta injection did not impair freezing at the end of
the fear conditioning trial when the context was the only available
CS. This indicates that Abeta injected mice were able to detect
both the CS (context) and the US (footshock). Since Abeta did not
impair freezing during fear conditioning, it is likely that learning
was unaffected and that the impaired retrieval of the contextual
fear memory was caused by impaired consolidation shortly after
fear conditioning. However, it can not be excluded that learning
was impaired by Abeta in a way that did not affect the immediate
expression of fear during fear conditioning. Future studies that
inject Abeta right after fear conditioning might be able to
distinguish between Abeta effects on learning and consolidation.
Either way, our data are in line with previous studies that have
reported effects of Abeta oligomers on learning and consolidation
[13,25,26].
Contextual fear memory is dependent on the hippocampus and
tone fear memory is independent from the hippocampus [23],
which suggests that the specific impairment of contextual fear
memory in our study was caused by Abeta oligomers that diffused
from the ventricle into the hippocampus. Accordingly, previous
studies found that injection of natural Abeta oligomers into the
lateral ventricle impaired synapse remodeling in the hippocampus
[27], and increased glutamate levels in the hippocampus [28]. Our
inability to detect an effect on tone fear memory might indicate
that an insufficient fraction of the injected Abeta reached the
amygdala, which is a brain region critical for formation of tone
fear memories [23]. Since together with the hippocampus, the
amygdala is one of the first brain regions affected in AD patients
[29], future studies could inject Abeta oligomers directly into the
amygdala to explore a possible role for the amygdala in AD
associated memory loss.
Our finding that natural Abeta oligomers acutely impair the
formation of a contextual fear memory is in agreement with
previous studies that injected synthetic Abeta oligomers into the
ventricle or hippocampus [25,26]. In contrast, another study that
injected synthetic Abeta oligomers into the hippocampus reported
an improvement of contextual fear memory, suggesting that low
levels of synthetic Abeta oligomers might have beneficial effects on
memory [30]. Since synthetic and natural Abeta oligomers have
different efficacy profiles [18,19], and no positive effect of natural
Abeta oligomers on memory has been reported yet, it remains to
be shown if low levels of natural Abeta oligomers can also have
positive effects on memory.
The results from our study are in agreement with other data that
support a causal role of soluble Abeta oligomers in AD associated
memory loss [1,2]. We used 7PA2 cells to produce a natural Abeta
oligomer solution that contained Abeta monomers, dimers, trimers,
and tetramers. These same Abeta oligomers were found in 7PA2
Figure 4. Experiment 3: single Abeta injection 2 hours before fear conditioning. Top) Diagram showing the design of experiment 3.
Separate groups of mice were injected one time with either control or Abeta solution 2 hours before fear conditioning. Bottom) Graphs showing
average freezing scores during fear conditioning on day 1 and the two retrieval trials on day 2. There was no difference during any of the intervals
analyzed between mice injected with the Abeta solution (n=10) and mice injected with the control solution (n=8). Error bars are standard errors of
means.
doi:10.1371/journal.pone.0029940.g004
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7PA2 Abeta oligomers found binding of Abeta oligomers to EphB2
protein, impaired in-vivo long-term potentiation, and impaired
memory as tested in the alternating lever cyclic ratio test, radial arm
maze, and passive avoidance test [9,12,15,27,34]. Importantly, the
natural Abeta oligomer solutionderived from 7PA2 cells used inthis
and other studies contains Abeta oligomer species similar to those
found in AD brain tissue, which when injected into rat brains also
impair memory [8]. It is therefore conceivable that injection of
7PA2 derived natural Abeta oligomers into the mouse brain
recapitulates a causal factor responsible for memory loss in AD
patients, and that the mechanism responsible for Abeta oligomer
impaired contextual fear conditioning also contributes to AD
associated memory loss.
In summary, we found an acute impairing effect of natural Abeta
oligomers on contextual fear memory in mice. This finding is in
agreement with natural Abeta oligomer induced memory impair-
ments found in previous studies that used rats [7,8,9,18,
27,34,35,36]. Our data show, to our knowledge, for the first time
that natural Abeta oligomers can also impair memory in mice. Our
studytherebypaves the wayforusinggeneticmousemodels tostudy
the underlying mechanisms by which natural Abeta oligomers
impair memory. This is also, to our knowledge, the first time that an
effect of natural Abeta oligomers on fear conditioning is reported.
Since fear conditioning requires only a single learning trial, it is
highly suitable for dissecting the different stages of memory
(acquisition, consolidation, storage, and retrieval), allowing to test
the contribution of each memory stage to AD associated memory
loss. We propose that natural Abeta oligomer impaired fear
conditioning can be used to test potential mechanisms and
treatments of AD associated memory loss. A better understanding
of the acute effects of natural Abeta oligomers might lead to
treatments that can reverse cognitive impairments during early
stages of AD, and possibly prevent or delay the progress of AD.
Materials and Methods
Ethics statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of Tufts University (Protocol Number: B2009-118). All
surgery was performed under xylazine/ketamine anesthesia, and
every effort was made to minimize suffering.
Natural amyloid-beta oligomer and control solutions
A solution containingnaturalamyloid-beta(Abeta) oligomerswas
derived from the conditioned medium of 7PA2 cells (a kind gift of
Dr. Dennis Selkoe), which are Chinese Hamster Ovary cells stably
transfected with cDNA encoding APP751, an amyloid precursor
protein that contains the Val717Phe familial Alzheimer’s disease
mutation [15,37]. Five million 7PA2 cells were cultured in
Dulbecco’smodified Eagle’smedium(DMEM,Hyclone)containing
10% bovine fetal calf serum (Atlanta Biologicals), 50 mg/ml
penicillin/streptomycin, 2 mM L-glutamine (Sigma-Aldrich), and
200 mg/ml G418 (Calbiochem). After 24 h cells were washed with
serum-free medium and conditioned in 5 ml of plain DMEM
lacking any additives, overnight. The oligomer-containing condi-
tioned medium (CM) was removed and cleared of cells by
centrifugation at 200 g for 10 min at 4uC. CM was then
concentrated 10-fold by centrifugation at 3500 g for 45 min using
Amicon Ultra-15(Millipore), and this concentrated CM was used as
the natural Abeta oligomer solution in the fear conditioning
experiments. The concentrated CM contained between 12,000–
14,000 pg/ml of Abeta42 as measured by ELISA. A control
solution was prepared by immunodepleting the concentrated CM
using the Abeta antibody 4G8 (Covance, SIG-39220-200).
Concentrated CM (250 microliter) was first pre-cleared with protein
A/G beads (Santa Cruz Biotechnology) for 1h at 4uC. Next, three
rounds of immunodepletion, 6h each at 4u, were performed using
protein A/G beads with 4G8 antibody (45 microliter of beads, 3
microgram of antibody per round). To ensure that all the antibody
used for immunodepletion was removed, concentrated CM was
post-cleared after the third IP round with protein A/G beads for 1h
at 4uC. Complete removal of Abeta oligomers was confirmed by 4–
12% BIS-TRIS minigels with MES immunoblotting (Invitrogen)
and the Abeta 6E10 detection antibody (Covance, SIG-39320-200).
In addition, we confirmed with immunoblotting that the immuno-
depletionhad noeffect onthe amountofsecreted amyloid precursor
protein. Aliquots of Abeta and control solutions were stored at
280uC until the day of injection.
Mice
For all experiments male C57Bl/6J mice were used. Mice were
ordered from Jackson Laboratories (Bar Harbor, Maine) at an age
of 9 weeks, and allowed to acclimate for at least one week before
surgery. Mice were housed in a climate controlled room under a
regular light/dark cycle withlights on at 7 am and lights off at 7 pm.
Surgery
Mice were anesthesized with an intraperitoneal injection of
xylazine/ketamine (10 mg/kg xylazine and 100 mg/kg ketamine)
and placed in a stereotaxic instrument. An incision was made to
expose the skull and one unilateral guide cannula (Plastics One;
C315GS-5-SPC, cut 1.5 mm below the pedestal) was implantedjust
above the dorsal lateral ventricle using stereotaxic coordinates
(AP=20.2 mm, ML=+1.0 mm, DV=21.5 mm relative to
bregma). One anchor screw (CMA Microdialysis; 7431021) and
cement (Fisher Scientific; Durelon Triple Cement Kit, NC9332928)
was used to attach the guide cannula to the skull. Sutures were used
to close the incision, a topical antibiotic was applied, and a dummy
was inserted into the guide cannula to prevent clogging (Plastics
One; C315DCS-5-SPC, cut to completely fill the guide cannula).
After the surgery, mice received subcutaneous injections of
buprenorphine (0.1mg/kg) and sterile saline (0.5 ml) for analgesia
and rehydration respectively. Mice recovered from the surgery for
at least 5 days before injection and behavioral testing started.
Injection
Aliquots of Abeta and control solutions were thawed, gently
tapped, and kept on ice until injection on the same day. Abeta and
control solutions were injected into the lateral ventricle while the
mice were awake and freely moving. This was achieved by
removing the dummy and placing an internal injector cannula
(Plastics One; C315IS-5-SPC, cut to extend 1 mm projection
below the tip of the guide cannula) into the guide cannula. The
injector cannula was connected by tubing (Plastics One; C313C,
40 cm) with a syringe (Hamilton; 701RN, 10 microliter with
removable blunt 22 gauge needle). Tubing was filled with sterile
water to enable sufficient pressure for injection. Abeta and control
solutions were drawn into the injector cannula and separated from
the sterile water in the tubing with an air bubble. All injections had
a 2 microliter volume and were administered over a 5 minute
period (400 nanoliter/minute) using an electronic micropump.
The injector cannula was left in the guide cannula for an
additional 5 minutes after injection to prevent flow into the
cannula track, after which the injector cannula was removed and
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returned to their home cage after each injection. Mice were
injected three times for experiment 1: 1 hour before and 3 hours
after the fear conditioning trial on day 1, and 1 hour before the
context retrieval trial on day 2. Mice were injected a single time for
experiments 2 and 3: 1 hour (experiment 2) or 2 hours
(experiment 3) before the fear conditioning trial on day 1.
Fear conditioning
Fear conditioning was done during the light phase between 9 am
– 5 pm. Each fear conditioning experiment consisted of 3 trials: one
fear conditioning trial on day 1, one context fear retrieval trial on
day 2, followed 3 hours later by a tone fear retrieval trial. For the
fear conditioning trial mice were placed in a rectangular box with
steel walls and a steel grid floor (Coulbourn Instruments; H10-11R-
TC, 120Wx100Dx120H). After a 3 minute baseline recording, a 20
second tone was presented (2800 Hz, 82 dB) that simultaneously
endedwitha 2secondfootshock(0.7 mA).One minute aftertheend
of the first tone-shock presentation a second similar tone-shock was
presented, and 1 minute after the second tone-shock presentation
mice were returned to their home cage. During the context fear
retrieval trial on day 2, mice were placed for a 3 minute period in
the same box used for the fear conditioning trial. For the tone fear
retrieval trial on day 2, mice were placed in a square plastic box
(Tupperware; 90Wx90Dx80H) with black and white striped walls,
bedding on the floor, and acetic acid scent. After a 3 minute
baseline recording, a 20 second tone was presented similar to the
tone used during the fear conditioning trial.
Histology
After behavioral testing was completed all mice were anesthetized
and injected with ink using the same method that was used for Abeta
and control injections. The brains were dissected, and the presence of
ink inside the lateral ventricle was verified. Mice that did not have ink
in the lateral ventricle were excluded from further analysis. This
resulted in the exclusion of 9 out of 56 mice (experiment 1: 5 out of
16; experiment 2: 2 out of 20; experiment 3: 2 out of 20).
Analysis of freezing behavior
Freezing behavior was quantified using automated analysis of
videos. A digital camera was mounted above each box used for fear
conditioning, and connected to a computer with Actimetrics
FreezeFrame software (Coulbourn Instruments). Videos were
collected during behavioral testing and analyzed after completion
of behavioral testing. Freezing was quantified with the FreezeFrame
software (bout length of 1 sec) for a number of time intervals. Time
intervals analyzed for the fear conditioning trial on day 1: 0–60 sec
(minute 1; m1), 60–120 sec (minute 2; m2), 120–180 sec (minute 3;
m3), 180–200 sec (tone 1; t1), 200–260 sec (inter-tone interval; iti),
260–280 sec (tone 2; t2), 280–340 sec (end). Time interval analyzed
for the context fear retrieval trial on day 2: 60–180 sec (context).
Time intervals analyzed for the tone retrieval trial on day 2: 60–
180 sec (pre-tone), 180–200 sec (tone). The first minute of both
retrieval trials was excluded from analysis, since mice show a short
period of hyperactivity after being moved from their home cage to a
new box. This period of hyperactivity interferes with freezing
behavior and thereby prevents reliable expression of conditioned fear
during the first minute. Statistical analysis was done using Student’s
unpaired t-tests to compare the control group with the Abeta group.
Supporting Information
Figure S1 Immunodepletion removes Abeta oligomers
but not secreted amyloid-precursor protein. Two images
are shown that cover the entire lanes that were labeled with the 6E10
antibody. The two images were taken using different settings because
ofthe large differences in theintensityofthebands inthe upper versus
lower part of the lanes. The immunoprecipitation resulted in the
removal of Abeta oligomers but not of secreted amyloid-precursor
protein (sAPP). The non-specific bands are most likely caused by the
4G8 antibody that was used for the immunoprecipitation.
(TIF)
Figure S2 Comparison between the three control
groups from experiment 1–3 and a group of mice that
was not subjected to surgery and injection. A) Repeated
injections of the control solution in experiment 1 increased freezing
during the context retrieval trial on day 2 compared with mice that
were never injected. Since mice were restrained for a short time
period every time the injector was placed in the guide cannula
before injection, we propose that repeated restraint stress caused by
the repeated injections might have caused a non-specific increase in
freezing on day 2. B–C) A single injection of control solution before
fear conditioning, as done in experiment 2 (B) and 3 (C), did not
significantly change freezing scores during the two retrieval trials on
day 2 as compared to mice not subjected to surgery and injection.
Error bars are standard errors of means. * P,0.05.
(TIF)
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